Potential factors correlating to the PMDA’s decision to waive Japanese Phase 2 and 3 studies for oncology drugs New Drug Application in Japan
Authors:
- 19 December 2012
- journal article
- phase iii-studies
- Published by Springer Nature in Investigational New Drugs
- Vol. 31 (4) , 1051-1055
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Anticancer drug development from traditional cytotoxic to targeted therapies: evidence of shorter drug research and development time, and shorter drug lag in JapanJournal of Clinical Pharmacy and Therapeutics, 2012
- The notorious “drug lag” for oncology drugs in JapanInvestigational New Drugs, 2011
- Clinical Development and Review Times for New Drugs in Japan: Associated FactorsClinical Pharmacology & Therapeutics, 2010
- Approval of new drugs 1999-2007: comparison of the US, the EU and Japan situationsJournal of Clinical Pharmacy and Therapeutics, 2010
- The Current Situation of Oncology Drug Lag in Japan and Strategic Approaches for Pharmaceutical CompaniesDrug Information Journal, 2009
- Personal imports of drugs to Japan in 2005 - an analysis of import certificatesJournal of Clinical Pharmacy and Therapeutics, 2008
- Characteriation of Clinical Data Packages Using Foreign Data in New Drug Applications in JapanClinical Pharmacology & Therapeutics, 2007